N@N

Andrew Berens Maintained (BPMC) at Hold with Decreased Target to $56 on, Jul 1st, 2022

Andrew Berens of SVB Leerink, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $60 to $56 on, Jul 1st, 2022.

Andrew has made no other calls on BPMC in the last 4 months.

There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 2 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $65 on, Tuesday, June 14th, 2022
• Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022

These are the ratings of the 4 analyists that currently disagree with Andrew

---

• Derek Archila of "Wells Fargo" Initiated at Sell and Held Target at $40 on, Monday, June 27th, 2022
• David Lebowitz of "Citigroup" Downgraded from Hold to Strong Sell and Decreased Target to $41 on, Friday, June 10th, 2022
• Eun Yang of "Jefferies" Upgraded from Hold to Strong Buy and Decreased Target to $78 on, Wednesday, June 1st, 2022
• Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $105 on, Friday, March 4th, 2022

Contributing Sources

---